These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 119815)

  • 1. [The changes of the OEP-HA titer in the sera of mice challenged with Pseudomonas aeruginosa and in the phagocytic system of macrophages in vitro (author's transl)].
    Satomi N; Haranaka K; Kunii O; Mashimo K
    Kansenshogaku Zasshi; 1979 Aug; 53(8):350-8. PubMed ID: 119815
    [No Abstract]   [Full Text] [Related]  

  • 2. [The influence of anti-OEP-IgG and -IgM upon mouse spleen macrophage. Phagocytic activity against Pseudomonas aeruginosa and OEP-coated latex granules (author's transl)].
    Haranaka K; Matsuo M; Satomi N; Kunii O; Mashimo K
    Kansenshogaku Zasshi; 1978 Nov; 52(11):482-9. PubMed ID: 107248
    [No Abstract]   [Full Text] [Related]  

  • 3. The role of OEP-antibodies in Pseudomonas aeruginosa infection.
    Doi T; Nakajima T
    Jpn J Exp Med; 1978 Aug; 48(4):287-95. PubMed ID: 101701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapeutic effects of anti-OEP-antibodies in the Pseudomonas aeruginosa (Fisher's seven serotypes) infection of mice and the influence of this antibody upon the phagocytic activity of mice spleen macrophages (author's transl)].
    Haranaka K; Satomi N; Matsuo M; Kunii O; Mashimo K
    Kansenshogaku Zasshi; 1979 Apr; 53(4):175-81. PubMed ID: 89175
    [No Abstract]   [Full Text] [Related]  

  • 5. [Studies on the Pseudomonas aeruginosa infections--frequency, antibiotics sensitivity, OEP-HA titer (author's transl)].
    Satomi N; Haranaka K; Fukaya K; Kunii O; Mashimo K
    Kansenshogaku Zasshi; 1979 Apr; 53(4):167-74. PubMed ID: 112204
    [No Abstract]   [Full Text] [Related]  

  • 6. Common protective antigen between Pseudomanas aeruginosa and Vibrio cholerae.
    Yamamoto A; Homma JY; Ghoda A; Ishihara T; Takeuchi S
    Jpn J Exp Med; 1979 Dec; 49(6):383-90. PubMed ID: 120454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective properties and haemagglutinins in serum from humans and in serum from mice injected with a new polyvalent Pseudomonas vaccine.
    Jones RJ; Roe EA
    Br J Exp Pathol; 1975 Feb; 56(1):34-43. PubMed ID: 812544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Dynamics of humoral antibody formation against the O-antigen of Pseudomonas aeruginosa in suppurative diseases].
    Zarubina EK; Svetukhin AM; Edvabnaia LS
    Khirurgiia (Mosk); 1980 Nov; (11):47-52. PubMed ID: 6777579
    [No Abstract]   [Full Text] [Related]  

  • 9. Role of nonagglutinating antibody in the protracted immunity of vaccinated mice to Pseudomonas aeruginosa infection.
    Moody MR; Kessel RW; Young VM; Fiset P
    Infect Immun; 1978 Sep; 21(3):905-13. PubMed ID: 101467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The first clinical trial of immuno's experimental Pseudomonas aeruginosa flagellar vaccines.
    Crowe BA; Enzersberger O; Schober-Bendixen S; Mitterer A; Mundt W; Livey I; Pabst H; Kaeser R; Eibl M; Eibl J
    Antibiot Chemother (1971); 1991; 44():143-56. PubMed ID: 1801633
    [No Abstract]   [Full Text] [Related]  

  • 11. Pseudomonas aeruginosa antibodies in human plasma.
    Doi T; Yoshioka M; Nakajima T
    Jpn J Exp Med; 1976 Jun; 46(3):149-54. PubMed ID: 60502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The differentiation of OEP-HA titer between gamma-globulin products for intravenous use and their effectiveness in the passive protection of mice against Pseudomonas aeruginosa infection (author's transl)].
    Haranaka K; Satomi N; Matsuo M; Fukaya K; Kunii O; Mashimo K
    Kansenshogaku Zasshi; 1978 Nov; 52(11):490-6. PubMed ID: 85678
    [No Abstract]   [Full Text] [Related]  

  • 13. [Protective effect of a corpuscular polyvalent Pseudomonas aeruginosa vaccine in generalized chronic Pseudomonas aeruginosa infection in mice with cyclophosphamide-induced leukopenia].
    Vetkova LG; Zaĭtsev LG; Khasman EL; Radkevich SA; Moroz AF
    Zh Mikrobiol Epidemiol Immunobiol; 1986 Mar; (3):14-8. PubMed ID: 3085409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Common protective antigen (OEP) of Pseudomonas aeruginosa.
    Abe C; Shionoya H; Hirao Y; Okada K; Homma JY
    Jpn J Exp Med; 1975 Oct; 45(5):355-9. PubMed ID: 817054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Basis for the potential production of immune preparations against Pseudomonas aeruginosa from the blood of convalescent burn patients].
    Povstianoĭ NE; Kolker II; Nazarchuk LV; Fedorovskaia EA; Litovchenko PP
    Gematol Transfuziol; 1984 Jul; 29(7):56-8. PubMed ID: 6205938
    [No Abstract]   [Full Text] [Related]  

  • 16. Role of antibody in infections due to Pseudomonas aeruginosa.
    Young LS
    J Infect Dis; 1974 Nov; 130 Suppl(0):S111-8. PubMed ID: 4213568
    [No Abstract]   [Full Text] [Related]  

  • 17. The enhancement of phagocytosis and intra-cellular killing of Pseudomonas aeruginosa and its common antigen (OEP) coated latex particles by mouse spleen macrophages to which anti-OEP-IgG and gentamicin have been added.
    Haranaka K; Matsuo M; Mashimo K
    Jpn J Exp Med; 1977 Feb; 47(1):35-40. PubMed ID: 404451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pseudomonas aeruginosa infection and vaccination in the rat.
    Kostiala AA
    J Med Microbiol; 1980 May; 13(2):201-12. PubMed ID: 6770090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of macrophage function for defence of the lung against Pseudomonas aeruginosa.
    Speert DP; Wong SY; Macdonald M; Sargeant R
    Behring Inst Mitt; 1997 Feb; (98):274-82. PubMed ID: 9382751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycolipoprotein from Pseudomonas aeruginosa as a protective antigen against P. aeruginosa infection in mice.
    Sensakovic JW; Bartell PF
    Infect Immun; 1977 Nov; 18(2):304-9. PubMed ID: 411754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.